Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 31 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		PharmacoEconomic Assessment IRESSA® in the Treatment of Non–Small-Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Natural history/Epidemiology, Treatment				Active				20 and over				Other				9461700718 NCT00173524


2.		Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				D7913C00046 NCT00536107


3.		Safety and Efficacy Study of Gefitinib In Patients With Non-Small Cell Lung Cancer(NSCLC) Without Tumor Progression After First-Line Platinum-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				Over 18				Other, Pharmaceutical / Industry				D7913L00071 NCT00769639


4.		Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Pharmaceutical / Industry				D7913L00071 NCT00770588


5.		Study Of Zd1839 (Iressa™) Versus Methotrexate For Previously Treated Patients With Squamous Cell Carcinoma Of The Head And Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				ZD1839IL/0704 NCT00072878


6.		Iressa Follow-up Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Natural history/Epidemiology, Treatment				Active				18 and over				Pharmaceutical / Industry				1839IL/0555 D7913L00008, NCT00357734


7.		Randomized Gefitinib Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				ONC-2008-001 NCT00807066

Last Modified: 8/10/2006 First Published: 6/23/2004


8.		Phase I/II Study of Gefitinib, Trastuzumab (Herceptin®), and Docetaxel in Patients With HER2/neu-Overexpressing Metastatic Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CHNMC-03049 IRB 03049, ZENECA-1839US/0274, ZENECA-IRUSIRES0012, NCT00086957


9.		A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				NP01/07/03 NCT00212108


10.		Hydroxychloroquine and Gefitinib to Treat Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				21 and over				Other, Pharmaceutical / Industry				NS 01/03/08 NCT00809237

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute